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Introduction
Delays to inpatient discharge from the hospital for medically ready patients are
associated with a large cost, both economically to the overall healthcare system and to
the individual patient. Several studies show that at a given institution, these unnecessary
hospitalization days can cost upwards of millions of dollars, not to mention the
additional risk of exposing patients to hospital-acquired infections.1,2 The reasons for
these delays are many and varied, but include individual complex social issues, ride
availability, poor follow-up, or an unprepared disposition plan.
At our institution (Stanford Health Care), we have observed that one contributing factor
is that prescribed discharge medications are not yet approved by a patient’s health insurance company at the time of discharge. Stanford has a diverse patient population with
many patients relying on state or federally funded government insurance programs,
which have limited drug formularies. Depending on a patient’s insurance, certain
medications need a prior authorization (PA) in order to be approved and affordable. This
process can take between hours to days and, if started at the time a patient is medically
ready for discharge, can delay the patient’s ability to safely leave the hospital.
It has been shown that medications requiring a PA take significantly longer to fill (one
study involved a median time of four days longer) than those that do not.3 Inability to
access medications upon discharge can negatively impact adherence, increasing risk
of post-discharge adverse drug events.4 Therefore, discharges are often delayed while
waiting for medications to receive prior authorization approval.
Based on our experience, there are no studies that evaluate delays due to discharge
medications needing to undergo the PA process. Thus, in our pilot study, we both
aim to define the scope of this problem by surveying resident physicians as well as
provide an intervention to identify earlier medications that will need to undergo a PA
process. Pharmacy-led interventions in processing PAs have resulted in a statistically
significant benefit in improving time to PA approval, fill, and pickup.5 Therefore, in our
intervention, we utilize a specialized “transitions of care” (TOC) pharmacist to analyze
the medications of patients who are predicted to be discharged and alert the medical
team of potential medications that may need PA approval, with the intended effect that
this process will start long before a patient is actually discharged.
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Methods
Setting
This study took place at Stanford Health
Care, a teaching academic center located
in Stanford, California. Stanford Hospital
is a 613-bed, urban medical center. This
intervention involved all five house-staff
inpatient general internal medicine wards
teams that are staffed by two interns, one
resident, and one attending, as well as one
to two medical students. The university
institutional review board notice of determination waived review for this study
since it was classified as quality improvement. The purpose of this project was to
optimize and improve local care.

Survey
Prior to implementing our intervention,
a nine-question survey was created and
electronically distributed to the Stanford
Internal Medicine Residency program
using Stanford University Qualtrics
software (July 2015). Questions assessed
the frequency of delays to discharge
related to medications and knowledge of
formulary information.

Intervention
Of the five teaching Internal Medicine
teams at our institution, two were
randomized into our intervention and
the remaining three served as control
teams. The intervention teams met daily
with a TOC pharmacist to review the
medication lists of upcoming discharges,
which were defined as patients predicted
to be discharged within 24-48 hours.
The TOC pharmacist would screen the
patient’s medication list for medications
that require a PA; call the outpatient
pharmacies to confirm medication stock,
insurance coverage and need for a PA; and
initiate the processing of the claim. This
information was then forwarded to the
medical team. If a patient did not leave
by the predicted discharge time, the TOC
pharmacist would ask the team to identify
a reason for the delayed discharge.

The control teams met daily with a resident physician and were similarly queried
about identifying upcoming discharges.
However, medications were not reviewed
with the team and the medical team was
not alerted of any medications that may
need a PA approval. If a patient did not
leave by the predicted discharge time, the
medical team would be asked to identify a
reason for the delayed discharge.
A PA list (Figure 1) was created by
TOC pharmacists at our institution as
a reference tool to identify medications
frequently requiring PA. The TOC
pharmacist in our intervention was
able to defer to this list to guide
recommendations. This list was also
provided to the control group so that
all five medical teams had the same
information available. However, only
the intervention team had daily rounds
with the TOC pharmacist to screen the
patient medication list and intervene in
the PA process.

Statistical Analysis
Patient data from the intervention and
from their medical chart were recorded in
Microsoft Excel. Data collected included
the patient’s predicted and actual discharge
date, length of stay (LOS), number of
PAs for discharge medications needed,
insurance company, number of days
delayed, and reason for delayed discharge.
Comparisons between the intervention
and control teams for the two primary
outcomes (delayed discharge by 24 hours
and number of days delayed for discharge)
were statistically analyzed with a Student’s
t-test. Mean length of stay was also
compared using a Student's t-test. Both the
intervention and control comparisons were
completed concurrently over a continuous
three-week period.

...in our intervention,
we utilize a specialized
“transitions of care” (TOC)
pharmacist to analyze the
medications of patients
who are predicted to be
discharged and alert the
medical team of potential
medications that may
need PA approval, with
the intended effect that
this process will start
long before a patient is
actually discharged.

Ethical Considerations
There were no identifiable ethical
considerations or conflicts of interest.
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Results

Intervention

Survey
A total of 72 resident physicians
responded to the survey with a response
rate of approximately 63%. The overwhelming majority (94%) had responded
that they had experienced delays in
discharge due to medication problems,
with a significant portion attributed to
not having PA approval in time (Table 1).
Additionally, 71% of residents responded
that they had limited knowledge of the
Stanford insurance formulary (Table 1).
Residents were also asked to identify
medications likely to require a PA
and were assessed on their ability to
correctly identify where to find insurance
information within the electronic health
record. The responses overwhelmingly
indicated little understanding of
medication formularies, with 98% unable
to correctly identify the number of
medications covered by MediCal.

A total of 66 patients were involved in
the intervention arm and 98 patients in
the control arm, with balanced demographics and insurance profiles (Table 2).
In the intervention arm, there were 20
discharge prescriptions needing PA,
while in the control arm there were
25 discharge prescriptions needing PA
(Table 2). The most common medications
requiring PA were oral vancomycin
(n=5) and enoxaparin (n=4). Figure 2
highlights the breakdown of medications
requiring PA in both the control and
intervention groups. Of these patients
discharged with a medication requiring a
PA, 4/25 patients were identified from the
control teams who experienced greater
than 24-hour delays to discharge due to
medications not having a PA approval
available at the time of discharge,
compared to 0/20 patients identified on
the intervention teams (P=0.06). When
comparing the number of extra hospital

days caused by delayed discharges
secondary to unsecured PAs per number
of potential discharges, there were six
days of extra hospitalization for patients
from the control group out of 27 potential
discharges compared to zero extra days
for patients from the intervention side
out of 20 potential discharges (P=0.02).
LOS for the intervention and control
teams was not significantly different
(6.3 vs 5.8 days, respectively; P=0.37).

Discussion;
Among internal medicine residents at
our institution, our survey showed that
it was not uncommon that discharges
were being delayed due to discharge
medications not having a completed
PA. We speculate that this could be
associated with late placement of
discharge prescriptions. If physicians do
not know a PA is required for a certain
medication, they may not place early

Table 1. Survey questions distributed to resident physicians and responses
Questions

Responses, n (%)

On average, how often have you
experienced delays in discharge due
to medication? (n=72)

Never:

1-2 times per year:

1-2 times per month:

1-2 times per week:

More than 2 times per week:

4 (6)

8 (11)

39 (54)

16 (22)

5 (7)

For the previous question, about
what percentage were due to not
having prior authorization?
(n=68)

0%:

25%:

50%:

75-100%:

Not sure:

7 (10)

20 (29)

18 (27)

13 (19)

10 (15)

On a scale of 1-5 (5 being the
most confident), how confident
are you in your knowledge of the
insurance formulary information
displayed in Epic (eg, the "tiers"
and "preferences" displayed when
prescribing discharge medications)?
(n=72)

1-Not confident at all:

2-Slightly confident:

3-Some confidence:

4-Confident:

5-Very confident:

51 (71)

13 (18)

7 (10)

1 (1)

0 (0)

On average, how many days before
discharge do you place discharge
medication orders?
(n=72)

At the time of discharge:

1 day prior:

2 days prior: 4 (6)

32 (44)

36 (50)

Please indicate your level of training. First-year resident:
(n=72)
20 (28)

Second-year resident:

Third-year resident:

29 (40)

23 (32)

The majority of respondents experienced medication-related delays to discharge, many of which were due to not having PA approval. Of 115 residents surveyed, 72 residents responded for a 63% response rate.
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discharge medication orders and start
the PA process earlier, thus possibly
delaying discharge. It has been shown
that anticipatory discharge orders,
in which discharge orders including
prescriptions are placed more than 24
hours before discharge, decreases LOS.6
Interestingly, our survey also showed a
dearth of knowledge regarding medical
coverage and insurance formularies
among resident physicians. Results
suggest that consideration of patient
insurance and formularies are not
necessarily taken into consideration
when prescribing. This may contribute to
medication-related access barriers. This
is an opportunity at our institution to
provide education to prescribers about
formulary considerations and enhance
available resources, including making
our PA list (Figure 1) widely available
while encouraging prescribers to seek a
pharmacist when needed.
Our intervention involves a third
party knowledgeable about medication
coverage earlier in the discharge process.
Collaborating with the TOC pharmacist
allows prescribers to identify and resolve

PAs in anticipation of discharge, as well as
improve prescribing in compliance with
patient-specific insurance formularies
by facilitating drug substitutions when
appropriate. By utilizing a specialized
TOC pharmacist, we were able to identify
discharge medications needing PA well
before discharge, saving six days of
unnecessary hospitalization compared
to control in a three-week time span.
Despite this, LOS between the two groups
was not significantly different as expected.
Many different factors determine LOS
so it is possible that one confounder or
outlier disproportionately affected one
group of our relatively small sample size.
While a pharmacy technician could also
be helpful in identifying medications
requiring PA, pharmacists are also able to
suggest therapeutic alternatives, which are
beyond the scope of pharmacy technicians.
Additionally, this practice was incorporated into the workflow of our TOC
pharmacists who already see patients at
discharge. Therefore, there were no additional costs associated. This did support
the need for collaborating with pharmacists in discharge planning. While

...our survey also showed
a dearth of knowledge
regarding medical
coverage and insurance
formularies among
resident physicians.
Results suggest that
consideration of patient
insurance and formularies
are not necessarily taken
into consideration when
prescribing.

Table 2. Patient characteristics and specific medications requiring PA
Characteristic, n (%)
Number of patients, n
Female
Average LOS, days

Intervention

Control

P-value

66

98

-

31 (47)

48 (49)

0.88

6.3

5.8

0.37

Number of patients with primary Medicare insurance

20 (30)

27 (28)

0.77

Number of patients with primary MediCal insurance

8 (12)

17 (17)

0.43

Number of patients with medications needing PA

20 (30)

25 (26)

0.61

Number of patients with delayed discharges due to unsecured PAs/number
of patients with medications needing a PA

0/20 (0)

4/25 (16)

0.06

Number of extra hospital days from delayed discharges due to unsecured
PAs/number of potential discharges among patients with medications
needing a PA

0/20 (0)

6/27 (22)

0.02

LOS, length of stay; PA, prior authorization.
Days of unnecessary hospitalization due to unsecured prior authorizations are significantly greater in the control group.
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Figure 1. PA list

To better help transition patients out of the hospital, we would like to provide this list for our prescribers to be
alerted and to be looking for medications that are known to be troublesome in the outpatient setting (prior
authorization, step therapy, TAR, high cost, etc) . DISCLAIMER: THIS MEDICATION LIST IS ONLY A REFERENCE
AND MAY NOT BE COMPREHENSIVE/
Diabetes•
Transplant
• Lantus Solostar (glargine)
• Prograf (tacrolimus)
medications
• Kwikpen (lispro/aspart)
• Rapamune (sirolimus)
• Ensure all pen products are covered
• Cellcept/Myfortic
(mycophenolate)
Please remember to prescribe test
strips, lancets, lancing device, and/or
Cyclosporine
control solutions for their home
• Mepron (atovaquone)
diabetic glucometers.

.

GU/GI

•
•

Xifaxan (rifaximin)
Rowasa (mesalamine enema)

Inhalers•

•
•
•
•

Advair
Qvar
Combivent
Pulmicort

Antibiotics

•
•
•
•

Zyvox (linezolid)
Vantin (cefpodoxime)
Levaquin (levofloxacin)
vancomycin oral (Vancocin) :
capsules/solution
vancomycin solution requires a
0
compounding pharmacy
Vfend (voriconazole)
Noxafil (posaconazole)

Pulmonary
Hypertension

Revatio (sildenafil)
Letairis (ambrisentan)
Tracleer (bosentan)
Adcirca (tadalafil)
Ventavis (iloprost)
Tyvaso (treprostinil inhalled)
Remodulin (treprostinil IV/SQ)
Flolan (epoprostenol)
Veletri (epoprostenol), etc .

Plavix (clopidogrel")
Brilinta (ticagrelor)
Effient (prasugrel)

Anticoagulants

•
•
•
•
•
•
•
•
•
•

•

lnjectables

.
Anti platelets

Others

•
•
•
•
•
•

•
•

Lidoderm patches
Growth factors : Neupogen
(filgrastim), Neulasta
(pegfilgrastim), Epogen/Procrit
(epoetin alpha), etc
Nimodipine (Nimotop)
Oral Chemotherapy Agents:
Dasatanib, lmmatanib, sprycel,
Gleevec, etc.

Asmanex
Xopenex
Breo Ellipta,
etc .

All novel anticoagulants•
Pradaxa (dabigatran)
0
Eliquis (apixaban)
0
Xarelto (rivaroxaban)
0
0
0
0

Antiarrhythmics

•
•
•

Lovenox (enoxaparin)
Arixtra (fondaparinux)
Fragmin (dalteparin)

• Multaq (dronedarone)
• Always check stock with
pharmacy for older
antiarrhythmics.

Please remember to prescribe syringes
and/or needles for all injectables if
not pre-filled.
Please seek prior authorization for all IV medications {eg. Cubicin (daptomycin), Te/Iara {ceftaroline), etc.}
Special formulations (eg. oral disintegrating tablets (ODT), wafers), may have higher costs.
If patient is already on a medication before com ing to the hospital, most likely the medication is already covered!
*Most insurance have a preferred formulary agent. Please refer if needing assistance.
"State of CA, Medi-Cal on ly
Prepared by Transitions of Care Pharmacy Connie Elejade, PharmD, BCPS, and Noah Fang, PharmD, BCPS
in collaboration with Case Management Team
Last Rev 1/2014
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In summary, these results suggest that
unnecessary hospitalization days due
to the need for PA can be saved with
standardized screening for the need
for PAs earlier than the discharge
date. Future research would benefit
from further evaluating the impact of
pharmacist involvement in the discharge
planning process to reduce LOS, reduce
health care-associated costs, and improve
health care-related outcomes. This would
further support including a pharmacist
on every medical team or partnering with
an outside outpatient pharmacy that can
expedite and complete all PA processes
for discharging patients.
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Medications
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advance of hospital discharge to reduce
medication-related barriers and their
potential consequences.
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